Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer (PROFILER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01774409|
Recruitment Status : Recruiting
First Posted : January 24, 2013
Last Update Posted : February 19, 2020
It is a non-randomized, multicentric, cohort study, combined with a biological sample collection, a clinical data collection and with a genetic and immunologic biomarkers study.
The ProfiLER program aims to implement a personalized cancer medicine approach by proposing to establish the genetic and immunologic profile of the tumor for patients with an advanced malignant tumor, in order to define a map of genetic (for the pre-identified target genes) and immunologic profiles for all the studied types of cancer. This study will also allow adapting the therapeutic management of these patients, if needed, by giving them targeted therapies or immunotherapies (commercialized on in ongoing clinical trials), based on the recommendations of the multidisciplinary molecular board.
The genetic and immunologic profile of the tumor will be determined from archival or fresh collected (biopsy of a reachable lesion) tumor sample and from a blood sample. The correlation between genetic profiles of the tumor, patients immunity status and clinical data (progression, tumor response, etc.) collected from the patient medical records will probably allow us to identify biomarkers with a potential predictive value and to determine if some genetic disorders are linked to immunity status alterations.
|Condition or disease||Intervention/treatment||Phase|
|Neoplasms||Genetic: Blood and tumor samples||Not Applicable|
Determination of the tumor profile and review in multidisciplinary molecular board:
The genetic and immunologic profile will be performed from the available tumor sample and from a blood sample.
- Research of mutations/insertions/deletions for an array of predefined genes in tumor deoxyribonucleic acid by high-throughput sequencing
- Analysis of copy number variations of genes on tumor deoxyribonucleic acid by microarray-based comparative genomic hybridization
- Analysis of rearrangements involving the gene Anaplastic Lymphoma Kinase that can't be detected by Next Generation Sequencing or array Comparative Genomic Hybridization (balanced translocations) by means of fluorescent hybridization probes on tumor samples Immunologic profile: analysis of the expression of relevant immunologic markers
Clinical data collection:
Patients' clinical data will be collected from the patient medical record. This study is not a treatment evaluation. Patients' follow-up and treatment will be performed according to the center local practices or to the specificities of a clinical trial in which the patient would have been enrolled, depending on the recommendations given by the multidisciplinary molecular board, with the review of the tumor genetic profile.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer|
|Study Start Date :||February 2013|
|Estimated Primary Completion Date :||July 2023|
|Estimated Study Completion Date :||July 2023|
|Experimental: Blood and tumor samples||
Genetic: Blood and tumor samples
Genetic: Establishment of the genetic and immunologic profile
Whole blood sampling :
Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.
With the established profile, recommendations will be given by a multidisciplinary molecular board.
- Establish a map of genetic profiles (for the pre-identified target genes) for all types of advanced malignant tumors. [ Time Frame: at least 3 years after patient enrollment ]Description of the incidence rates of each detected genetic disorder among the pre-identified target genes in the global cohort and for each histological type.
- Establish a map of immunologic profiles for all types of advanced malignant tumors. [ Time Frame: at least 3 years after patient enrollment ]Description of the incidence rates of each detected immunologic disorder in the global cohort and for each histological type.
- Determine for each histological type of tumor, characteristic profiles of genetic and/or immunologic disorders and disorders that might be common to several histological types. [ Time Frame: at least 3 years after patient enrollment ]Comparison of the genetic and immunologic profiles between patients with the same tumor type or between tumors of different types.
- Identify genetic and/or immunologic biomarkers (or molecular profiles) with a potential predictive value on response to treatments. [ Time Frame: at least 3 years after patient enrollment ]Tumor response (determined by the investigator and/or the radiologist) assessed after each treatment received by the patient during his/her whole participation to the study (if data are available in the medical record).
- Identify biomarkers (constitutional or somatic alterations in tumor cells) that might be correlated with systemic or local alterations of the immunity status observed in some patients with advanced cancers [ Time Frame: at least 3 years after patient enrollment ]lymphopenia, over-representation of Treg, dendritic cells alterations,
- Assess the changes of genetic and/or immunologic profiles in case of progressive disease [ Time Frame: at least 3 years after patient enrollment ]
- Number of patients with a recommanded therapy based on their molecular profil and/or for whom the therapy hs been administrated and description of the recommanded therapy [ Time Frame: at least 3 years after patient enrollment ]A description will be done of therapie(s) recommanded and/or received by patients based on recommandation done by the Molecular Tumor Board after reviewing of molecular profil
- Describe the clinical impact of this molecular profiling in term of PFS [ Time Frame: at least 3 years after patient enrollment ]Progression free survival for each recommanded therapies received
- Describe the clinical impact of this molecular profiling in term of OS [ Time Frame: at least 3 years after patient enrollment ]Overall survival for each recommanded therapies received
- Describe the clinical impact of this molecular profiling in term of tumor response [ Time Frame: at least 3 years after patient enrollment ]Tumoral response (clinic and/or radiologic) for each recommanded therapies received
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01774409
|Contact: Jean-Yves BLAY, MD||+33 4 78 78 51 firstname.lastname@example.org|
|Groupement Hospitalier Mutualiste||Recruiting|
|Grenoble, France, 38028|
|Principal Investigator: Cécile LEYRONNAS, MD|
|Hôpital Edouard Herriot||Not yet recruiting|
|Lyon, France, 69003|
|Principal Investigator: Julien FORESTIER, MD|
|Sub-Investigator: Catherine LOMBARD BOHAS, MD|
|Sub-Investigator: Thomas WALTER, MD|
|Centre Léon Bérard||Recruiting|
|Lyon, France, 69008|
|Sub-Investigator: Thomas BACHELOT, MD|
|Sub-Investigator: Amine BELHABRI, MD|
|Sub-Investigator: Christophe BERGERON, MD|
|Sub-Investigator: Pierre BIRON, MD|
|Sub-Investigator: Helen BOYLE, MD|
|Sub-Investigator: Philippe CASSIER, MD|
|Sub-Investigator: Patrick COMBEMALE, MD|
|Sub-Investigator: Françoise DESSEIGNE, MD|
|Sub-Investigator: Cécile FAURE-CONTER, MD|
|Sub-Investigator: Jérome FAYETTE, MD|
|Sub-Investigator: Aude FLECHON, MD|
|Sub-Investigator: Christelle DE LA FOUCHARDIERE, MD|
|Sub-Investigator: Didier FRAPPAZ, MD|
|Sub-Investigator: Hervé GHESQUIERES, MD|
|Sub-Investigator: Jean-Paul GUASTALLA, MD|
|Sub-Investigator: Pierre GUIBERT, MD|
|Sub-Investigator: Pierre-Etienne HEUDEL, MD|
|Sub-Investigator: Aurélien MARABELLE, MD|
|Sub-Investigator: Sylvie NEGRIER, MD|
|Sub-Investigator: Eve-Marie NEIDHARDT, MD|
|Sub-Investigator: Emmanuelle NICOLAS-VIRELIZIER, MD|
|Sub-Investigator: Maurice PEROL, MD|
|Sub-Investigator: Isabelle RAY-COQUARD, MD|
|Sub-Investigator: Paul REBATTU, MD|
|Sub-Investigator: Catherine SEBBAN, MD|
|Sub-Investigator: Olivier TREDAN, MD|
|Sub-Investigator: Alice LEVARD, MD|
|Sub-Investigator: Virginie AVRILLON, MD|
|Sub-Investigator: Louis TASSY, MD|
|Centre Hospitalier Lyon Sud||Recruiting|
|Pierre-Bénite Cedex, France, 69495|
|Principal Investigator: Benoît YOU, MD|
|Sub-Investigator: Cécile FOURNEL-FEDERICO, MD|
|Sub-Investigator: Gilles FREYER, MD|
|Sub-Investigator: Sophie TARTAS, MD|
|Sub-Investigator: Véronique TRILLET-LENOIR, MD|
|Institut de cancérologie LUCIEN NEUWIRTH||Recruiting|
|Saint-Priest-en-Jarez, France, 42270|
|Principal Investigator: Olivier COLLARD, MD|
|Principal Investigator:||Jean-Yves BLAY, MD PhD||Centre Leon Berard|